Drug Trial Radar · NCT06659757
A Study to Investigate the Safety and Tolerability of Single and Multiple Ascending Doses of KIT2014 in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Aug 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
56
Actual
Start
Oct 16, 2024
Primary completion
Jul 14, 2025
Study completion Jul 14, 2025
Sponsor
- Lead sponsor
- Kither Biotech SrlIndustry
- Sponsor type
- Industry
- Collaborators
- Avance Clinical Pty Ltd.
- First posted
- Oct 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is the first-in-human study with KIT2014 designed to provide safety, tolerability and pharmacokinetic data in healthy volunteers.
Conditions
- Cystic Fibrosis
Interventions
KIT2014Drug
KIT2014 will be administered by inhalation with a nebuliser
PlaceboOther
Placebo will be administered by inhalation with a nebuliser
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment-emergent adverse events (TEAEs), serious adverse events (SAEs)Time frame: Up to 10 days post-dose in SAD and up to 14 days after the last dose in MAD
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CMAX Clinical Research Pty Ltd
Adelaide, South Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.